PRAXIS PRECISION MEDICINES, INC. Comprehensive Income
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Comprehensive Income of -$84.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$84.80M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$94.72M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$88.85M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$73.83M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$303.36M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$182.16M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$123.10M.
- PRAXIS PRECISION MEDICINES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$214.03M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$84.80M 10-Q · filed 2026-08-06 | -$179.52M 10-Q · filed 2026-08-06 | -$268.36M derived: sum of 3 quarters · filed 2026-08-06 | -$342.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$94.72M 10-Q · filed 2026-05-07 | -$183.57M derived: sum of 2 quarters · filed 2026-05-07 | -$257.39M derived: sum of 3 quarters · filed 2026-05-07 | -$328.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$88.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$162.68M derived: sum of 2 quarters · filed 2026-02-19 | -$234.07M derived: sum of 3 quarters · filed 2026-08-06 | -$303.36M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$73.83M 10-Q · filed 2025-11-05 | -$145.22M derived: sum of 2 quarters · filed 2026-08-06 | -$214.51M 10-Q · filed 2025-11-05 | -$273.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$71.39M 10-Q · filed 2026-08-06 | -$140.68M 10-Q · filed 2026-08-06 | -$200.04M derived: sum of 3 quarters · filed 2026-08-06 | -$250.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$69.29M 10-Q · filed 2026-05-07 | -$128.65M derived: sum of 2 quarters · filed 2026-05-07 | -$179.16M derived: sum of 3 quarters · filed 2026-05-07 | -$211.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$59.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$109.86M derived: sum of 2 quarters · filed 2026-02-19 | -$142.62M derived: sum of 3 quarters · filed 2026-02-19 | -$182.16M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$50.51M 10-Q · filed 2025-11-05 | -$83.26M derived: sum of 2 quarters · filed 2025-11-05 | -$122.81M 10-Q · filed 2025-11-05 | -$149.69M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$32.75M 10-Q · filed 2025-08-04 | -$72.30M 10-Q · filed 2025-08-04 | -$99.18M derived: sum of 3 quarters · filed 2026-02-19 | -$123.81M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$39.55M 10-Q · filed 2025-05-02 | -$66.43M derived: sum of 2 quarters · filed 2026-02-19 | -$91.06M derived: sum of 3 quarters · filed 2026-02-19 | -$125.35M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$26.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$51.51M derived: sum of 2 quarters · filed 2026-02-19 | -$85.80M derived: sum of 3 quarters · filed 2026-02-19 | -$123.10M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$24.63M 10-Q · filed 2024-11-06 | -$58.92M derived: sum of 2 quarters · filed 2024-11-06 | -$96.23M 10-Q · filed 2024-11-06 | -$137.04M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$34.29M 10-Q · filed 2024-08-13 | -$71.59M 10-Q · filed 2024-08-13 | -$112.40M derived: sum of 3 quarters · filed 2024-08-13 | -$156.21M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$37.30M 10-Q · filed 2024-05-13 | -$78.11M derived: sum of 2 quarters · filed 2024-05-13 | -$121.91M derived: sum of 3 quarters · filed 2024-05-13 | -$182.18M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$40.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$84.61M derived: sum of 2 quarters · filed 2024-03-05 | -$144.88M derived: sum of 3 quarters · filed 2024-03-05 | -$214.03M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$43.80M 10-Q · filed 2023-11-07 | -$104.07M derived: sum of 2 quarters · filed 2023-11-07 | -$173.22M 10-Q · filed 2023-11-07 | -$231.95M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$60.27M 10-Q · filed 2023-08-09 | -$129.41M 10-Q · filed 2023-08-09 | -$188.15M derived: sum of 3 quarters · filed 2023-08-09 | -$232.83M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$69.15M 10-Q · filed 2023-05-11 | -$127.88M derived: sum of 2 quarters · filed 2023-05-11 | -$172.56M derived: sum of 3 quarters · filed 2023-05-11 | -$208.93M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$58.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$103.41M derived: sum of 2 quarters · filed 2023-02-07 | -$139.78M derived: sum of 3 quarters · filed 2023-02-07 | -$167.24M 10-K · filed 2023-02-07 |
| 2021-09-30 | -$44.68M 10-Q · filed 2022-11-09 | -$81.05M derived: sum of 2 quarters · filed 2022-11-09 | -$108.50M 10-Q · filed 2022-11-09 | -$134.21M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$36.37M 10-Q · filed 2022-08-08 | -$63.82M 10-Q · filed 2022-08-08 | -$89.53M derived: sum of 3 quarters · filed 2022-08-08 | -$105.75M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$27.46M 10-Q · filed 2022-05-09 | -$53.16M derived: sum of 2 quarters · filed 2022-05-09 | -$69.38M derived: sum of 3 quarters · filed 2022-05-09 | -$80.95M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$25.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$41.92M derived: sum of 2 quarters · filed 2022-02-28 | -$53.49M derived: sum of 3 quarters · filed 2022-02-28 | -$61.82M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$16.22M 10-Q · filed 2021-11-03 | -$27.78M derived: sum of 2 quarters · filed 2021-11-03 | -$36.11M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$11.57M 10-Q · filed 2021-08-16 | -$19.90M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$8.33M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |